Business Description
Bangkok Genomics Innovation PCL
ISIN : THB972010003
Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.33 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 0.3 | |||||
Interest Coverage | 34.41 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 6.82 | |||||
Beneish M-Score | -0.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.6 | |||||
3-Year EBITDA Growth Rate | -9.1 | |||||
3-Year EPS without NRI Growth Rate | -15.3 | |||||
3-Year Book Growth Rate | 30.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.72 | |||||
9-Day RSI | 47.5 | |||||
14-Day RSI | 51.12 | |||||
3-1 Month Momentum % | 54.89 | |||||
6-1 Month Momentum % | 64.8 | |||||
12-1 Month Momentum % | 31.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.58 | |||||
Quick Ratio | 4.29 | |||||
Cash Ratio | 1.75 | |||||
Days Inventory | 41.68 | |||||
Days Sales Outstanding | 91.23 | |||||
Days Payable | 69.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.48 | |||||
Dividend Payout Ratio | 0.67 | |||||
Forward Dividend Yield % | 2.48 | |||||
5-Year Yield-on-Cost % | 2.48 | |||||
Shareholder Yield % | 2.36 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 41.01 | |||||
Operating Margin % | 13.07 | |||||
Net Margin % | 11.95 | |||||
EBITDA Margin % | 18.67 | |||||
FCF Margin % | -33.88 | |||||
OCF Margin % | -24.32 | |||||
ROE % | 8.46 | |||||
ROA % | 7.21 | |||||
ROIC % | 20.18 | |||||
3-Year ROIIC % | -12.42 | |||||
ROC (Joel Greenblatt) % | 26.51 | |||||
ROCE % | 8.81 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.21 | |||||
Forward PE Ratio | 40.8 | |||||
PE Ratio without NRI | 27.21 | |||||
Price-to-Owner-Earnings | 26.46 | |||||
PEG Ratio | 2.25 | |||||
PS Ratio | 3.22 | |||||
PB Ratio | 2.22 | |||||
Price-to-Tangible-Book | 2.32 | |||||
EV-to-EBIT | 20.8 | |||||
EV-to-EBITDA | 14.48 | |||||
EV-to-Revenue | 2.7 | |||||
EV-to-FCF | -8.35 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.22 | |||||
Price-to-Graham-Number | 1.67 | |||||
| Price-to-Net-Current-Asset-Value | 2.83 | |||||
| Price-to-Net-Cash | 17 | |||||
Earnings Yield (Greenblatt) % | 4.8 | |||||
FCF Yield % | -10.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bangkok Genomics Innovation PCL Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ฿) | 379.511 | ||
| EPS (TTM) (฿) | 0.075 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 55.52 | ||
| 14-Day RSI | 51.12 | ||
| 14-Day ATR (฿) | 0.079248 | ||
| 20-Day SMA (฿) | 2.066 | ||
| 12-1 Month Momentum % | 31.21 | ||
| 52-Week Range (฿) | 1.2 - 2.28 | ||
| Shares Outstanding (Mil) | 600 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bangkok Genomics Innovation PCL Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bangkok Genomics Innovation PCL Stock Events
| Event | Date | Price (฿) | ||
|---|---|---|---|---|
| THB 0.050000 Cash Dividend | 2026-05-06 | 1.43 (+0.00%) | ||
| THB 0.050000 Cash Dividend | 2025-05-06 | 1.89 (+0.00%) |
Show
Entries
Bangkok Genomics Innovation PCL Frequently Asked Questions
What is Bangkok Genomics Innovation PCL(BKK:BKGI)'s stock price today?
The current price of BKK:BKGI is ฿2.04. The 52 week high of BKK:BKGI is ฿2.28 and 52 week low is ฿1.20.
When is next earnings date of Bangkok Genomics Innovation PCL(BKK:BKGI)?
The next earnings date of Bangkok Genomics Innovation PCL(BKK:BKGI) is .
Does Bangkok Genomics Innovation PCL(BKK:BKGI) pay dividends? If so, how much?
The Dividend Yield %  of Bangkok Genomics Innovation PCL(BKK:BKGI) is 2.48% (As of Today), Highest Dividend Payout Ratio of Bangkok Genomics Innovation PCL(BKK:BKGI) was 0.67. The lowest was 0.66. And the median was 0.66. The  Forward Dividend Yield % of Bangkok Genomics Innovation PCL(BKK:BKGI) is 2.48%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Bangkok Genomics Innovation PCL
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers